Metabolism-Modulating Compositions for Cancer Stem Cell Elimination
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Cancer stem cells (CSCs) are resistant to traditional treatments, leading to relapse and metastases due to their ability to self-renew and differentiate, necessitating compositions and methods to induce cell death effectively.
Innovation Solution
A combination of metabolism modulating agents, including venetoclax, azacitidine, and other compounds, is administered to target and induce cell death in cancer stem cells, modulating cellular pathways to enhance treatment efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional treatment methods (chemotherapy, radiation therapy) are used, then general cancer treatment is provided, but cancer stem cells persist due to resistance, leading to relapse and metastases
Solution Approach 1:
The patent changes the metabolic parameters of cancer stem cells by using combination therapy with venetoclax (BCL-2 inhibitor), azacitidine (DNA methyltransferase inhibitor), and etomoxir (fatty acid oxidation inhibitor). This multi-parameter metabolic disruption overcomes the resistance of cancer stem cells to traditional treatments by targeting their unique metabolic dependencies on oxidative phosphorylation and fatty acid oxidation.
Solution Approach 2:
The patent employs a composite treatment approach combining three different metabolism modulating agents with distinct mechanisms of action. This composite therapy strategy targets multiple metabolic pathways simultaneously (mitochondrial function, DNA methylation, fatty acid metabolism), creating a synergistic effect that overcomes cancer stem cell resistance more effectively than single-agent therapies.
2Reliability
If combination therapy with multiple metabolism modulating agents is used, then cell death in cancer stem cells is induced, but treatment complexity increases
Solution Approach 1:
The patent segments the treatment approach by assigning each metabolism modulating agent a specific target: venetoclax targets BCL-2-mediated apoptosis resistance, azacitidine targets epigenetic regulation and DNA methylation, and etomoxir targets fatty acid oxidation. This segmentation allows each agent to address a specific vulnerability in cancer stem cells while maintaining overall treatment coordination.
Data Source
AI summary
Compositions and methods for reducing cancer stem cells and/or treating cancer are provided. In some aspects, the compositions and methods can comprise at least one metabolism modulating agent. In other aspects, the compositions and methods can comprise at least two metabolism modulating agents.